Thailand News in Brief
from Thai PBS WorldThailand and the world, every day
Swipe upto start reading / next story
Scroll downto start reading / next story
Key points summarised by AI
Check them against the full article
Long-Acting Antibody treatment to be provided to those suffering immunodeficiency
Yesterday 07:41Key points summarised by AI
- Thailand secures 257,500 doses of Long-Acting Antibodies (LAAB) from AstraZeneca to protect immunocompromised individuals from severe COVID-19.
- The LAAB procurement repurposes funds from an existing AstraZeneca vaccine contract, requiring no additional government budget.
- Composed of Tixagevimab and Cilgavimab, LAAB are long-acting monoclonal antibodies designed to prevent SARS-CoV-2 from entering human cells.
- Approved for emergency use in Thailand and globally, LAAB is administered prophylactically to eligible patients and demonstrates 83% effectiveness in reducing severe illness.
Read full article
News1/3
Skip >Skip >